ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1102

Immunoreactive Collagen Type II Cleavage Products and Their Nitrated Forms in Rheumatoid Arthritis and Osteoarthritis: An Outpatient Cross-Sectional Study

Ruediger Mueller1, Axel Finckh2, Guy Heynen3 and Johannes von Kempis4, 1Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, 2Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland, 3Consulting, CH-6300 Zug, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, collagen and rheumatoid arthritis (RA), OA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Catabolism of type II collagen (COLII) involves multiple metalloproteinases, aggrecanases and cathepsin, releasing heterogeneous triple helix cleavage products. The complex regulation of these enzymes and of inducible NOS (iNOS)includes inflammatory cytokines. Col2-1 peptide (Col), located towards the N-telopeptide region of COLII contains a tyrosine residue susceptible to endogenous nitration by reactive nitrogen species, forming Col-2-1-NO2 (NCol). Specific immunoassays allow for estimation of nitration index (NI). Using these assays in OA and RA should show differences since RA, unlike OA, is treated with DMARDs known to inhibit structural damage progression.

Methods:

Serum (S) and Urine (U) Col and NCol were measured by ELISA in a cross-sectional study (49 RA and 118 outpatients with active hand OA). The ratio of NCol (nmol)/Col (nmol) provided NI. Clinical variables were age, sex, DAS and VAS. Urinary fractional excretions (UFE) of biomarkers was calculated in RA patients.Statistical analysis used STATA® Version 12.1

Results:

OA patients were older (64 years vs 58 in RA). Mean DAS28 was 2.64 with 60% receiving corticoids or synthetic and biological DMARD treatment in RA. VAS pain was higher in OA than RA patients (46 vs. 34;p<0.0001). Mean SCol concentrations (nmol/l) and SNCol (pmol/l) were higher in RA (308±17 and 687 ±90) than OA (241 ± 13 and 465±39; p<0.0001). Mean UCol (nmol/mmol creatinine) was higher in RA than in OA (16.3 vs. 8.1; p<0.0001) whereas UNCol (pmol/mmol creatinine) values were similar between the 2 groups (22.4 ±4.3 in RA and 26.2 ±2.1 in OA; p>0.1). Col and NCol UFE were 2.87% (2.25-3.48; 95%CI) in RA and 2.63 % (1.81-3.46; 95%CI) and highly correlated (r-square=0.53; p<0.0001).The SCol2-1NI was similar in RA (0.238 %, 95% CI: 0.214-0.262) and in OA (0.217, 95% CI: 0.19-0.24; p>0.05) but the UCol2-1NI was markedly lower in RA (0.164, 95%CI: 0.141-0.187) than OA (0.37, 95%CI: 0.33-0.42; p<0.0001). In both RA and OA, pairwise comparisons of serum and urine NI indicated highly significant differences ( p<0.0001). None of the disease activity indices were associated with any of the two biomarkers or their ratios in serum or urine.

Conclusion:

Data indicate excess nitrated forms of Col2-1 in the urine of patients suffering from active OA in comparison to DMARD treated RA patients, indicating that a greater proportion of OA SNCol immunoreactive forms pass through the renal glomerular membrane than in RA. In RA, fractional excretion of both Col and NCol was low and similar for Col and NCol, excluding a differential renal handling of the detected epitopes. The excess of urinary nitrated forms in OA vs RA may result from the OA disease process itself or from DMARD interference with the iNOS activity in RA. Within patients’ differences between serum and urine NI values indicate biological heterogeneity of immunoreactive species containing the Col2-1 epitope. The clinical relevance of this heterogeneity is unknown since the half-life of measured components have not been studied. Additional investigations with specific enzyme inhibitors in OA and biological DMARDs in early RA are warranted to quantify the dynamics of serum and urine components of Col2-1 and its nitrated forms.


Disclosure:

R. Mueller,
None;

A. Finckh,

Roche, Pfizer, BMS,

2,

Roche, Pfizer, BMS,

5;

G. Heynen,

Artialis SA,

5;

J. von Kempis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoreactive-collagen-type-ii-cleavage-products-and-their-nitrated-forms-in-rheumatoid-arthritis-and-osteoarthritis-an-outpatient-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology